+++ Mögen Sie uns? Unseren Service, unsere Produkte, unser Pricing? Dann freuen wir uns über Ihr Lob und Ihre Wahl von BNP Paribas zu Ihrem Lieblings-Emittenten +++-w-
23.09.2021 18:00

Global Antibiotics Partnering Deals Report/Directory 2021: Trends, Players and Financials 2014-2021

Folgen
Werbung

DUBLIN, Sept. 23, 2021 /PRNewswire/ -- The "Global Antibiotics Partnering Terms and Agreements 2010 to 2021" report has been added to ResearchAndMarkets.com's offering.

Research and Markets Logo

The Global Antibiotics Partnering Terms and Agreements 2010 to 2021 report provides an understanding and access to the antibiotics partnering deals and agreements entered into by the worlds leading healthcare companies.

  • Trends in antibiotics partnering deals
  • Disclosed headlines, upfronts, milestones and royalties by stage of development
  • Antibiotics partnering contract documents
  • Top antibiotics deals by value

The Global Antibiotics Partnering Terms and Agreements report provides an understanding and access to the antibiotics partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides a detailed understanding and analysis of how and why companies enter antibiotics partnering deals. The majority of deals are early development stage whereby the licensee obtains a right or an option right to license the licensors antibiotics technology or product candidates. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

This report provides details of the latest antibiotics agreements announced in the healthcare sectors, covering:

  • Antibiotics
  • Aminoglycosides
  • Cephalosporin
  • Clindamycin
  • Macrolides
  • Penicillin
  • Quinolones
  • Sulfonamides
  • Tetracycline

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.

This report contains over 300 links to online copies of actual antibiotics deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.

Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.

For example, analyzing actual company deals and agreements allows assessment of the following:

  • What is actually granted by the agreement to the partner company?
  • What exclusivity is granted?
  • What are the precise rights granted or optioned?
  • What is the payment structure for the deal?
  • How are sales and payments audited?
  • What is the deal term?
  • How are the key terms of the agreement defined?
  • How are IPRs handled and owned?
  • Who is responsible for commercialization?
  • Who is responsible for development, supply, and manufacture?
  • How is confidentiality and publication managed?
  • How are disputes to be resolved?
  • Under what conditions can the deal be terminated?
  • What happens when there is a change of ownership?
  • What sublicensing and subcontracting provisions have been agreed?
  • Which boilerplate clauses does the company insist upon?
  • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
  • Which jurisdiction does the company insist upon for agreement law?

Global Antibiotics Partnering Terms and Agreements 2010 to 2021 includes:

  • Trends in antibiotics dealmaking in the biopharma industry since 2010
  • Analysis of antibiotics deal structure
  • Access to headline, upfront, milestone and royalty data
  • Access to over 300 antibiotics deal records and contract documents where available
  • The leading antibody deals by value since 2010
  • Most active antibiotics dealmakers since 2010
  • The leading antibiotics partnering resources

In Global Antibiotics Partnering Terms and Agreements 2010 to 2021, the available contracts are listed by:

  • Company A-Z
  • Headline value
  • Stage of development at signing
  • Deal component type
  • Specific therapy and technology target

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Key Topics Covered:

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in antibiotics dealmaking
2.1. Introduction
2.2. Antibiotics partnering over the years
2.3. Most active antibiotics dealmakers
2.4. Antibiotics partnering by deal type
2.5. Antibiotics partnering by therapy area
2.6. Antibiotics partnering by industry sector
2.7. Deal terms for antibiotics partnering
2.7.1 Antibiotics partnering headline values
2.7.2 Antibiotics deal upfront payments
2.7.3 Antibiotics deal milestone payments
2.7.4 Antibiotics royalty rates
2.8. The anatomy of an antibiotics deal
2.8. a. Case study 1: RRD International & Dipexium Pharmaceuticals
2.8.b. Case study 2: Hospira & Cempra Pharmaceutical
2.8.c. Case study 3: Astellas & Optimer Pharmaceuticals

Chapter 3 - Leading antibiotics deals
3.1. Introduction
3.2. Top antibiotics deals by value

Chapter 4 - Most active antibiotics dealmakers
4.1. Introduction
4.2. Most active antibiotics dealmakers
4.3. Most active antibiotics partnering company profiles

Chapter 5 - Antibiotics contracts dealmaking directory
5.1. Introduction
5.2. Antibiotics contracts dealmaking directory

Chapter 6 - Antibiotics dealmaking by technology type

  • Antibiotics
  • Aminoglycosides
  • Cephalosporin
  • Clindamycin
  • Macrolides
  • Metronidazole
  • Penicillin
  • Quinolones
  • Tetracycline

Chapter 7 - Partnering resource center
7.1. Online partnering
7.2. Partnering events
7.3. Further reading on dealmaking

Companies Mentioned

  • 3B Pharmaceuticals
  • A*STAR Agency for Science
  • Technology and Research
  • Achaogen
  • Actavis (name changed to Allergan)
  • Acurx Pharmaceuticals
  • Akorn
  • Allegis Holdings
  • Allergan
  • Almirall
  • Amerigen Pharmaceuticals
  • AMR
  • Anatara Lifesciences
  • Angelini Pharma
  • ANI Pharmaceuticals
  • Antibiotic Research UK
  • Appili Therapeutics
  • Aqua Pharmaceuticals
  • Arrevus
  • AstraZeneca
  • Australian Research Council
  • Aytu BioScience
  • Basilea Pharmaceutica
  • Biomedical Advanced Research and Development Authority
  • bioMerieux
  • Biophore Pharmaceuticals
  • Boston Pharmaceuticals
  • Boston University
  • Boulos and Cooper Pharmaceuticals
  • California Institute for Biomedical Research
  • Cantab Anti-infectives
  • CARB-X
  • Cardiome Pharma
  • Cempra Pharmaceutical
  • Centre for Drug Research and Development (CDRD)
  • Cepheid
  • Checkpoint Therapeutics
  • Cidara Therapeutics
  • Cipla
  • Citius Pharmaceuticals
  • Civica Rx
  • Covance
  • Crestone Pharma
  • CSPC Pharmaceutical Group
  • Cubist Pharmaceuticals
  • Cumberland Pharmaceuticals
  • CURx Pharmaceuticals
  • Dana-Farber Cancer Institute
  • Debiopharm
  • Decibel Therapeutics
  • Defence Science and Technology Laboratory
  • Defense Threat Reduction Agency
  • Deinove
  • Department of Defense
  • Department of Health and Human Services
  • Dipexium Pharmaceuticals
  • Discuva
  • DSM Sinochem Pharmaceuticals
  • Durata Therapeutics
  • Eddingpharm
  • Eli Lilly
  • Emergent BioSolutions
  • Entasis Therapeutics
  • Enterome Bioscience
  • Euprotec
  • Eurofarma
  • Everest Medicines
  • Evolva
  • Evotec
  • Federal Ministry of Education and Research (BMBF)
  • Fedora Pharmaceuticals
  • Ferrer International
  • Flemish agency for Innovation by Science and Technology
  • Foamix
  • FOB Synthesis
  • Forge Therapeutics
  • Foundation for Innovative New Diagnostics
  • FSC Laboratories
  • Galapagos
  • Genentech
  • Geom Therapeutics
  • Gilead Sciences
  • GlaxoSmithKline
  • Global Antibiotic Research and Development Partnership
  • Hackensack Meridian Health
  • Harvard Medical School

For more information about this report visit https://www.researchandmarkets.com/r/yw6f28

Media Contact:
Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com      

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1904
Fax (outside U.S.): +353-1-481-1716

Cision View original content:https://www.prnewswire.com/news-releases/global-antibiotics-partnering-deals-reportdirectory-2021-trends-players-and-financials-2014-2021-301384094.html

SOURCE Research and Markets

Jetzt kostenlos anmelden!

Es gibt es viele mittelständische Firmen, die mit stabilem Umsatz- und Gewinnwachstum glänzen. Trading-Profi Simon Betschinger stellt Ihnen als Anleger im Online-Seminar heute um 19 Uhr spannende deutsche Nebenwerte vor, mit denen Sie an der Börse profitieren können.
Jetzt kostenlos anmelden!
Werbung
Werbung
Werbung
Werbung
Börse Stuttgart Anlegerclub
Werbung

Heute im Fokus

DAX leichter -- Asien schließt in Rot -- Deutsche Bank steigert Quartalsgewinn -- BASF hebt nach starkem Quartal Jahresziele erneut an -- Innogy, Alphabet, Microsoft, Twitter-im Fokus

WACKER CHEMIE übernimmt Mehrheit an chinesischer Sico. Iberdrola mit sinkendem Gewinn in neun Monaten. AUDI baut offenbar Batterie-Kompetenzzentrum in Neckarsulm. Wieder offener Streit zwischen Betriebsrat und VW-Chef Diess. PUMA erhöht nach starkem 3. Quartal erneut die Prognose. US-Expertengremium spricht sich für BioNTech-Impfung für Kinder aus. GfK: Konsumklima legt weiter zu.

Umfrage

Würden Sie eine verpflichtende Corona-Impfung gutheißen?

finanzen.net zero
finanzen.net zero

Oskar

ETF-Sparplan

Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.
Zur klassischen Ansicht wechseln